HOME >> BIOLOGY >> NEWS
Gene-specific Ebola therapies protect non-human primates from lethal disease

Scientists have developed a successful strategy for interfering with Ebola virus infection that protected 75 percent of nonhuman primates exposed to the lethal disease. This is the first successful antiviral intervention against filoviruses like Ebola in nonhuman primates. The findings could serve as the basis for a new approach to quickly develop virus-specific therapies for known, emerging, and genetically engineered pathogens.

In today's online issue of the journal Public Library of Science Pathogens, a research team led by Sina Bavari and colleagues at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) reports using novel "antisense" drugs to interrupt normal Ebola virus replication. The work was performed in collaboration with AVI BioPharma, a U.S. biotechnology firm.

According to the study's authors, antisense drugs are useful against viral diseases because they are designed to enter cells and eliminate viruses by preventing their replication. The drugs, which act by blocking critical viral genetic sequences, may be more potent than anti-virals such as protease inhibitors, which seek to inhibit a protein needed for viral replication.

Ebola virus causes hemorrhagic fever with case fatality rates as high as 80 percent in humans. The virus, which is infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), is of concern both as a global health threat and a potential agent of biological warfare or terrorism. Currently there are no available vaccines or therapies.

"One advantage of this strategy is that it directly targets the virus," said the paper's first author, Kelly L. Warfield. "With Ebola infection, the virus grows so fast that it overtakes the host immune system. What we did, essentially, was to hold off the viral replication long enough for the host to mount an immune response and clear the virus."

Working with a class of compounds known a
'"/>

Contact: Caree Vander Linden
Caree.Vanderlinden@us.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
12-Jan-2006


Page: 1 2

Related biology news :

1. Ebola outbreaks killing thousands of gorillas and chimpanzees
2. Ebola-outbreak kills 5000 gorillas
3. Gorilla susceptibility to Ebola virus: the cost of sociality
4. Charting the path of the deadly Ebola virus in central Africa
5. Poaching, logging, and outbreaks of Ebola threaten central African gorillas and chimpanzees
6. Ebola virus: from wildlife to dogs
7. Study links Ebola outbreaks to animal carcasses
8. New asthma gene could lead to new therapies
9. Scientists decode RNA mystery, will help aim drug therapies
10. Genomic signatures identify targeted therapies for lung cancer
11. Existence of muscle-building stem cells points to regenerative therapies for muscular disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2019)... ... December 04, 2019 , ... ... has launched Subnovii Advanced Plasma Technology for U.S. dermatologists, plastic surgeons ... is the only plasma to employ LF technology – low frequency plus a ...
(Date:11/27/2019)... ... November 26, 2019 , ... Smile ... Ellyn, IL practice for Invisalign® treatment. Invisalign orthodontics uses a series ... a misaligned bite, also known as malocclusion, present both functional and cosmetic concerns. ...
(Date:11/22/2019)... ... November 21, 2019 , ... The inventors of a new ... a major step forward with that therapy, known as SurVaxM. MimiVax LLC principals ... off from Roswell Park in 2012, has entered into a China-exclusive licensing agreement ...
Breaking Biology News(10 mins):
(Date:1/22/2020)... ... 2020 , ... COBO Technologies and Cardea Bio partner to ... agreed to co-develop and market a portfolio of CRISPR QC products and services ... longer-term, the parties aim to develop a COBO branded QC device based on ...
(Date:1/10/2020)... (PRWEB) , ... January 09, 2020 , ... ... of Drug Development establishes benchmarks for the vendor qualification process, a critical ... Report, the process volume and complexity of the vendor qualification process creates delays ...
(Date:1/10/2020)... ... January 09, 2020 , ... ... announced its inaugural GenScript Biotech Global Forum on Jan. 14 in San Francisco, ... "Cell and Gene Therapy and the Booming China Market," will feature gene and ...
(Date:1/8/2020)... ... 2020 , ... RMA of Connecticut , a leading ... family, has announced that five of their Board-Certified reproductive endocrinologists have been honored ... publishing company Castle Connolly has compiled the list of America’s Top ...
Breaking Biology Technology:
Cached News: